cyclosporine A

ApprovedSmall molecule

Novartis

cyclosporine A is one of 655 small molecule programs targeting Cardiac Arrest. It is currently in Approved.

Indications

Total Trials

Active Trials

654

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrestActive, not recruiting

Liver TransplantActive, not recruiting

HepatitisApproved

Insulin SecretionActive, not recruiting

Eye DiseaseActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

Abdominal Aortic AneurysmActive, not recruiting

LeukemiaActive, not recruiting

KeratoconjunctivitisActive, not recruiting

Dry Eye SyndromeActive, not recruiting

Cardiac ArrestPhase 3

Active, not recruiting

Liver TransplantApproved

Active, not recruiting

HepatitisApproved

Approved

Insulin SecretionApproved

Active, not recruiting

Eye DiseasePhase 2

Active, not recruiting

Acute Myocardial InfarctionPhase 3

Active, not recruiting

Abdominal Aortic AneurysmPhase 2

Active, not recruiting

LeukemiaPhase 3

Active, not recruiting

KeratoconjunctivitisApproved

Active, not recruiting

Dry Eye SyndromePhase 3

Active, not recruiting

Showing 10 of 24 indications

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

cyclosporine A

Novartis

Approved

1 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Non-Malignant Disorders

NCT04644016

Q3 2027

Phase 3Recruiting

Treatment

NCT06658002

Q1 2028

N/ARecruiting

Hematological Diseases

NCT01962636

Phase 2Recruiting

Study completion

NCT05946772

Phase 2/3Recruiting

Allogeneic Hematopoietic Stem Cell Transplantation

NCT07366801

Q3 2030

Phase 3Not yet recruiting

Severe Aplastic Anemia

NCT07345000

Clinical

Trials by Indication[1]

Atopic Dermatitis4 trials

Investigation of Flare and Remission in Subjects With Atopic Dermatitis

Withdrawn· LEO Pharma logo

LEO Pharma·Phase 4·NCT03710044

Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis

Completed·UUniversity of Aarhus·N/A·NCT02226068·20 enrolled

Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

Completed·RRockefeller University·N/A·NCT01149759·9 enrolled

Show 1 more trial

A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients

Completed· Novartis logo

Novartis·Phase 2·NCT01552629·22 enrolled

Treatment3 trials

a Retrospective Study on the Systemic Treatment of LPP and FFA

Completed·EErasmus Medical Center··NCT06512766·315 enrolled

Cyclosporine a Pretreatment and Kidney Graft Function

Completed·UUniversity Hospital, Clermont-Ferrand·Phase 4·NCT02907554·648 enrolled

Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A

Recruiting·UUniversity of California, San Francisco·Phase 3·NCT06658002·150 enrolled

Severe Aplastic Anemia3 trials

A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07345000·210 enrolled

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

Completed· Novartis logo

Novartis·Phase 2·NCT04328727·36 enrolled

Combination Therapy of Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001964·104 enrolled

Kidney Transplant3 trials

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Completed· Novartis logo

Novartis·Phase 3·NCT00251004·833 enrolled

Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients

Completed· Pfizer logo

Pfizer·Phase 3·NCT00038948·830 enrolled

A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00402168·173 enrolled

Renal Transplant2 trials

Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients

Completed·UUniversity Hospital, Rouen·Phase 3·NCT00213590·208 enrolled

Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids

Completed· Novartis logo

Novartis·Phase 3·NCT00658320·122 enrolled

48 more indications

Lupus Nephritis2 trials

Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study

Completed·—·Phase 2·NCT00976300·40 enrolled

Multicenter Registry of Pediatric Lupus Nephritis in China

Unknown status·XXiqiang Dang··NCT03791827·1,200 enrolled

Conditioning2 trials

Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT

Unknown status·SSichuan University·Phase 2·NCT03336632·50 enrolled

Pharmacological Postconditioning During the Aortic Valvular Surgery

Completed·HHospices Civils de Lyon·Phase 3·NCT00987207·56 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation2 trials

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2/3·NCT07366801·64 enrolled

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Terminated·MMontefiore Medical Center·Phase 1·NCT02653196·1 enrolled

Renal Transplant Recipients2 trials

Calcineurin Free Immunosuppression in Renal Transplant Recipients

Completed·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT00812123·127 enrolled

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00634920·204 enrolled

Transplantation2 trials

Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation

Completed·UUniversity of Oslo School of Pharmacy·Phase 4·NCT00139009·30 enrolled

Postconditioning by Cyclosporin A in Pulmonary Transplantation

Withdrawn·HHospices Civils de Lyon·Phase 3·NCT02876250

Thalassemia1 trial

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT04009525·823 enrolled

Bone Marrow Failure Disorders1 trial

Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

Recruiting·SShandong Qilu Stem Cells Engineering Co., Ltd.·Phase 1/2·NCT05794425·100 enrolled

Newly Diagnosed1 trial

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

Completed·BBing Han·Phase 4·NCT04470804·56 enrolled

Eye Disease1 trial

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

Completed·NNovaliq GmbH·Phase 2·NCT02617667·207 enrolled

Dry Eye Syndrome1 trial

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)

Completed·SSirion Therapeutics, Inc.·Phase 3·NCT00549289

Cardiac Arrest1 trial

Cyclosporine A in Cardiac Arrest

Completed·HHospices Civils de Lyon·Phase 3·NCT01595958·796 enrolled

Interaction1 trial

Interaction Between Rimonabant and Cyclosporine and Tacrolimus

Completed·UUniversity of Oslo School of Pharmacy·Phase 4·NCT00525681·18 enrolled

Hematological Diseases1 trial

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01962636·200 enrolled

Refractory1 trial

Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

Withdrawn· Amgen logo

Amgen·Phase 2·NCT05323617

Renal Failure1 trial

Metabolic Pattern of Cyclosporine A and Acute Renal Failure

Completed·UUniversity of Oslo School of Pharmacy·Phase 4·NCT00264355·30 enrolled

Hypertrophic Cardiomyopathy1 trial

Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001965·32 enrolled

Renal Transplant Rejection1 trial

Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection

Completed·UUniversity of Giessen··NCT00150891·84 enrolled

Inherited Metabolic Disorders1 trial

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01043640·46 enrolled

Combination Therapy1 trial

A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.

Completed· Roche logo

Roche·Phase 3·NCT02091414·36 enrolled

Heart Transplant1 trial

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00862979·162 enrolled

Photobiomodulation1 trial

Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus

Completed·UUniversity of Seville·Phase 1·NCT07239128·160 enrolled

Randomized1 trial

Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study

Completed·—·Phase 3·NCT04714099·40 enrolled

Stem Cell Transplant1 trial

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Completed·UUniversity of Nebraska·Phase 2·NCT00571662·76 enrolled

Immune Tolerance1 trial

Immune Tolerance Study With Aldurazyme® (Laronidase)

Completed· Sanofi logo

Sanofi·Phase 1/2·NCT00741338·7 enrolled

Hematopoietic Stem Cell Transplant1 trial

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01626092·3 enrolled

Psoriasis1 trial

Comparison Study of Psoriasis Severity Assessment Tools

Completed·SSeoul National University Hospital·Phase 4·NCT02655705·34 enrolled

Keratoconjunctivitis1 trial

Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda

Completed·UUniversity Hospital, Ghent·Phase 4·NCT01211327·366 enrolled

Non-malignant Disorders1 trial

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04644016·31 enrolled

Drug Interactions1 trial

Drug/Drug Interactions With F901318

Withdrawn·FF2G Biotech GmbH·Phase 1·NCT03095547

Hepatitis1 trial

Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis

Completed·TTehran University of Medical Sciences·Phase 3·NCT01170351·55 enrolled

Myelodysplastic Syndromes1 trial

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00840827·6 enrolled

Abdominal Aortic Aneurysm1 trial

Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02225756·360 enrolled

Renal Transplantation1 trial

Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation

Terminated·MMedical University of Vienna·Phase 2·NCT01268995·32 enrolled

Juvenile Idiopathic Arthritis1 trial

Cyclosporine A in the Treatment of Juvenile Idiopathic Arthritis (JIA) Associated Chronic Anterior Uveitis

Completed·—··NCT00404482·60 enrolled

Insulin Secretion1 trial

Effects of Cyclosporine A on Pancreatic Insulin Secretion

Completed·UUniversity of Oslo School of Pharmacy·Phase 4·NCT00139035·16 enrolled

AML1 trial

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Completed·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 3·NCT02461121·156 enrolled

Hepatitis C1 trial

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

Terminated· Novartis logo

Novartis·Phase 4·NCT00260208·361 enrolled

ISS1 trial

Swiss Dermatology Network of Targeted Therapies (SDNTT)

Recruiting·SSwiss Dermatology Network for Targeted Therapies··NCT01706692·1,121 enrolled

Acute Myocardial Infarction1 trial

CYCLosporinE A in Reperfused Acute Myocardial Infarction

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT01650662·410 enrolled

Primary Sjögren Syndrome1 trial

Low Dose Cyclosporin A in Primary Sjögren Syndrome

Completed·—·Phase 2·NCT01693393·30 enrolled

Ulcerative Colitis1 trial

Efficacy of Cyclosporine Rescue Therapy in Acute Ulcerative Colitis.

Completed·TTampere University Hospital··NCT05219656·182 enrolled

Liver Transplant1 trial

Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00149994·171 enrolled

Chronic Graft Versus Host Disease1 trial

A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease

Completed·SStanford University·N/A·NCT00350545·37 enrolled

Brain Injury1 trial

Traumatic Brain Injury and Effects of Acute Cyclosporine A

Withdrawn·—·Phase 1/2·NCT02496975

Allogeneic Stem Cell Transplantation1 trial

Allogeneic Stem Cell Transplantation for Children With CML

Completed·SSt. Anna Kinderkrebsforschung·Phase 2/3·NCT02707393·13 enrolled

Leukemia1 trial

Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)

Completed·MMedical College of Wisconsin·Phase 3·NCT00412360·224 enrolled

Renal Allograft Recipients1 trial

A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04877288·102 enrolled

Unspecified2 trials

Cyclosporine In Takotsubo Syndrome

Recruiting·UUniversity Hospital Heidelberg·Phase 2·NCT05946772·204 enrolled

T&B Depletion Non Malignant

Unknown status·FFranco Locatelli·Phase 2·NCT01810926·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 69 trial records for cyclosporine A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cyclosporine A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cyclosporine A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

cyclosporine A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q1 2028

Q3 2030

Trials by Indication[1]

Atopic Dermatitis4 trials

Treatment3 trials

Severe Aplastic Anemia3 trials

Kidney Transplant3 trials

Renal Transplant2 trials

Lupus Nephritis2 trials

Conditioning2 trials

Allogeneic Hematopoietic Stem Cell Transplantation2 trials

Renal Transplant Recipients2 trials

Transplantation2 trials

Thalassemia1 trial

Bone Marrow Failure Disorders1 trial

Newly Diagnosed1 trial

Eye Disease1 trial

Dry Eye Syndrome1 trial

Cardiac Arrest1 trial

Interaction1 trial

Hematological Diseases1 trial

Refractory1 trial

Renal Failure1 trial

Hypertrophic Cardiomyopathy1 trial

Renal Transplant Rejection1 trial

Inherited Metabolic Disorders1 trial

Combination Therapy1 trial

Heart Transplant1 trial

Photobiomodulation1 trial

Randomized1 trial

Stem Cell Transplant1 trial

Immune Tolerance1 trial

Hematopoietic Stem Cell Transplant1 trial

Psoriasis1 trial

Keratoconjunctivitis1 trial

Non-malignant Disorders1 trial

Drug Interactions1 trial

Hepatitis1 trial

Myelodysplastic Syndromes1 trial

Abdominal Aortic Aneurysm1 trial

Renal Transplantation1 trial

Juvenile Idiopathic Arthritis1 trial

Insulin Secretion1 trial

AML1 trial

Hepatitis C1 trial

ISS1 trial

Acute Myocardial Infarction1 trial

Primary Sjögren Syndrome1 trial

Ulcerative Colitis1 trial

Liver Transplant1 trial

Chronic Graft Versus Host Disease1 trial

Brain Injury1 trial

Allogeneic Stem Cell Transplantation1 trial

Leukemia1 trial

Renal Allograft Recipients1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News